Screener
MoonLake Immunotherapeutics MLTX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income, net | 3,208 | 7,097 |
| Loss before income tax | (69,085) | (40,406) |
| Income tax expense | (622) | (153) |
| Net loss | $(69,707) | $(40,559) |
| Of which: net loss attributable to controlling interests shareholders | (69,707) | (39,944) |
| Of which: net loss attributable to noncontrolling interests shareholders | — | (615) |
| Net unrealized gain (loss) on marketable securities and short-term investments | 77 | (2,756) |
| Actuarial gain (loss) on employee benefit plans | (359) | 95 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's net income?
- MoonLake Immunotherapeutics (MLTX) reported net income of -$69.71M in Q1 2026.
- How has MoonLake Immunotherapeutics's net income changed year-over-year?
- MoonLake Immunotherapeutics's net income decreased by 71.9% year-over-year, from -$40.56M to -$69.71M.
- What is the long-term trend for MoonLake Immunotherapeutics's net income?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's net income has grown at a 42.4% compound annual growth rate (CAGR), from -$55.96M to -$230.32M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about MoonLake Immunotherapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude